ProCE Banner Activity

Contemporary Topics in Treating Myelofibrosis: A Conversation Between Experts

Clinical Thought

Experts discuss key topics in managing patients with myelofibrosis, including approaches to patients with low platelets, defining JAK inhibitor failure, and emerging therapeutic strategies.

Released: April 07, 2023

Share

Faculty

John Mascarenhas

John Mascarenhas, MD

Director, Adult Leukemia Program
Leader, Myeloproliferative Disorders Clinical Research Program
Division of Hematology/Oncology
Tisch Cancer Institute 
Professor of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York

Ruben A. Mesa

Ruben A. Mesa, MD

President
Enterprise Cancer Service Line
Executive Director
Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Enterprise Senior Vice President
Atrium Health
Vice Dean for Cancer Programs
Wake Forest University School of Medicine
Professor of Medicine
Wake Forest University School of Medicine
Winston-Salem, North Carolina

Provided by

ProCE Banner

Supporters

This activity is supported by an educational grant from

GSK

Incyte Corporation

PharmaEssentia Corp

Disclosure

Primary Author

John Mascarenhas, MD

Director, Adult Leukemia Program
Leader, Myeloproliferative Disorders Clinical Research Program
Division of Hematology/Oncology
Tisch Cancer Institute 
Professor of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York

John Mascarenhas, MD: consultant/advisor/speaker: AbbVie, Bristol-Myers Squibb, CTI Bio, Geron, GlaxoSmithKline, Incyte, Kartos, Novartis, Roche.

Ruben A. Mesa, MD

President
Enterprise Cancer Service Line
Executive Director
Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Enterprise Senior Vice President
Atrium Health
Vice Dean for Cancer Programs
Wake Forest University School of Medicine
Professor of Medicine
Wake Forest University School of Medicine
Winston-Salem, North Carolina

Ruben A. Mesa, MD, FACP: consultant: AbbVie, Blueprint, Bristol-Myers Squibb, CTI, Genentech, Geron, GlaxoSmithKline, Incyte, Novartis, Sierra, Telios; researcher: AbbVie, Blueprint, Bristol-Myers Squibb, CTI, Genentech, Incyte, MorphoSys, Sierra.